CompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...

Join the live Q&A on PrEP, the latest in HIV prevention. Text your questions to 713-526-1111 and tune in Monday to learn ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

A new HIV drug, lenacapavir, appears highly effective against strains circulating in Uganda, according to a study led by ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.

Foster City, California Thursday, February 20, 2025, 12:00 Hrs [IST] ...

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

New research has found little natural resistance to a new HIV therapy, adding to evidence that it may be a powerful tool in ...

Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...